Fred Hutch Study Dramatically Expands Therapeutic Range of Approved Kinase Drugs

Large-scale analysis reveals new uses for existing therapies across cancer types and non-cancer diseases. Rare cancer expert, Taran Gujral, PhD, uses his lab at Fred Hutch Cancer Center to investigate a promising target for cancer drugs — enzymes called kinases, which send signals regulating almost every activity in a healthy cell’s life cycle including growth, division and the controlled death of damaged cells.